Long-term outcome of renal transplantation in light-chain deposition disease

被引:154
作者
Leung, N
Lager, DJ
Gertz, MA
Wilson, K
Kanakiriya, S
Fervenza, FC
机构
[1] Mayo Clin & Mayo Fdn, Dept Internal Med, Div Nephrol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Anat Pathol, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Dept Internal Med, Div Hematol, Rochester, MN 55905 USA
关键词
light-chain deposition disease (LCDD); kidney transplantation; monoclonal gammopathy;
D O I
10.1053/j.ajkd.2003.09.020
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Light-chain deposition disease (LCDD) is a monoclonal gammopathy characterized by nonamyloid deposition of light chain in various organs. A small number of kidney transplantations have been performed on LCDD patients in whom end-stage renal disease (ESRD) developed. Methods: The authors retrospectively reviewed the clinical and histologic findings and outcome of 7 patients with LCDD who underwent kidney transplantation at our institution. Results: Renal insufficiency, hypertension, and proteinuria were present in all 7 patients. Proteinuria level was greater than 3.5 g/24 h in 3 patients. Three patients had microscopic hematuria. Monoclonal protein was detected in the serum in 3 patients, urine in 5, and was undetectable in 2. Median age at presentation was 42.7 (range, 33 to 58) years. The most common renal biopsy findings were mesangial expansion, mesangial nodules, tubular basement membrane thickening, and tubular atrophy. Kappa light chain was detected in all 7 renal biopsy results. Five patients were on dialysis before transplantation. LCDD recurred after a median of 33.3 (range, 2 to 45) months in 5 of the 7 patients. One patient remains on dialysis, whereas the other 4 have died. One patient died of progression of multiple myeloma 3 months after kidney transplantation without evidence of recurrence. Only 1 patient remains recurrence free after 13 years with normal renal allograft function. Conclusion: Although long-term benefits are occasionally seen, renal allograft survival is reduced significantly in LCDD patients. Kidney transplantation should not be an option for LCDD patients unless measures have been taken to reduce light chain production.
引用
收藏
页码:147 / 153
页数:7
相关论文
共 25 条
[1]  
BONAR L, 1969, P SOC EXP BIOL MED, V131, P1373
[2]   MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE - LIGHT CHAIN AND LIGHT AND HEAVY-CHAIN DEPOSITION DISEASES AND THEIR RELATION TO LIGHT CHAIN AMYLOIDOSIS - CLINICAL-FEATURES, IMMUNOPATHOLOGY, AND MOLECULAR ANALYSIS [J].
BUXBAUM, JN ;
CHUBA, JV ;
HELLMAN, GC ;
SOLOMON, A ;
GALLO, GR .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :455-464
[3]  
COMOTTI C, 1993, CONTRIB NEPHROL, V105, P133
[4]  
CONFALONIERI R, 1988, NEPHROL DIAL TRANSPL, V2, P150
[5]  
DAVIDNETO E, 1989, TRANSPLANT P, V21, P2128
[6]   Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease [J].
Dember, LM ;
Sanchorawala, V ;
Seldin, DC ;
Wright, DG ;
LaValley, M ;
Berk, JL ;
Falk, RH ;
Skinner, M .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (09) :746-753
[7]   LIGHT-CHAIN DEPOSITION DISEASE - ITS RELATION WITH AL-TYPE AMYLOIDOSIS [J].
GANEVAL, D ;
NOEL, LH ;
PREUDHOMME, JL ;
DROZ, D ;
GRUNFELD, JP .
KIDNEY INTERNATIONAL, 1984, 26 (01) :1-9
[8]  
GERLAG PGG, 1986, CLIN NEPHROL, V25, P101
[9]   Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL) [J].
Gertz, MA ;
Lacy, MQ ;
Gastineau, DA ;
Inwards, DJ ;
Chen, MG ;
Tefferi, A ;
Kyle, RA ;
Litzow, MR .
BONE MARROW TRANSPLANTATION, 2000, 26 (09) :963-969
[10]   Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report [J].
Gertz, MA ;
Lacy, MQ ;
Dispenzieri, A .
BONE MARROW TRANSPLANTATION, 2000, 25 (05) :465-470